A multivalent vaccine and single platform diagnostic for bacterial respiratory diseases of pigs
Lead Research Organisation:
London School of Hygiene & Tropical Medicine
Department Name: Infectious and Tropical Diseases
Organisations
- London School of Hygiene & Tropical Medicine (Lead Research Organisation)
- Department for Environment Food and Rural Affairs (Co-funder)
- Defence Science & Technology Laboratory (DSTL) (Collaboration)
- VabioTech (Collaboration)
- MSD Wellcome Trust Hilleman Laboratories (Collaboration)
- MERCK (Collaboration)
Publications
Faulds-Pain A
(2013)
Improved bacterial mutagenesis by high-frequency allele exchange, demonstrated in Clostridium difficile and Streptococcus suis.
in Applied and environmental microbiology
Da Silva GC
(2022)
Identification of small RNAs associated with RNA chaperone Hfq reveals a new stress response regulator in Actinobacillus pleuropneumoniae.
in Frontiers in microbiology
Bossé JT
(2015)
Identification of dfrA14 in two distinct plasmids conferring trimethoprim resistance in Actinobacillus pleuropneumoniae.
in The Journal of antimicrobial chemotherapy
Bossé JT
(2016)
ICEApl1, an Integrative Conjugative Element Related to ICEHin1056, Identified in the Pig Pathogen Actinobacillus pleuropneumoniae.
in Frontiers in microbiology
Weinert LA
(2015)
Genomic signatures of human and animal disease in the zoonotic pathogen Streptococcus suis.
in Nature communications
Luan SL
(2013)
Generation of a Tn5 transposon library in Haemophilus parasuis and analysis by transposon-directed insertion-site sequencing (TraDIS).
in Veterinary microbiology
Eberle KC
(2020)
Generation and Evaluation of a Glaesserella (Haemophilus) parasuis Capsular Mutant.
in Infection and immunity
Howell KJ
(2013)
Gene content and diversity of the loci encoding biosynthesis of capsular polysaccharides of the 15 serovar reference strains of Haemophilus parasuis.
in Journal of bacteriology
Pereira MF
(2015)
Galleria mellonella is an effective model to study Actinobacillus pleuropneumoniae infection.
in Microbiology (Reading, England)
Hau S
(2020)
Evaluation of the recombinant proteins RlpB and VacJ as a vaccine for protection against Glaesserella parasuis in pigs
in BMC Veterinary Research
Bossé JT
(2020)
Draft Genome Sequences of the Type Strains of Actinobacillus indolicus (46K2C) and Actinobacillus porcinus (NM319), Two NAD-Dependent Bacterial Species Found in the Respiratory Tract of Pigs.
in Microbiology resource announcements
Maglennon GA
(2013)
Development of a self-replicating plasmid system for Mycoplasma hyopneumoniae.
in Veterinary research
Howell KJ
(2015)
Development of a Multiplex PCR Assay for Rapid Molecular Serotyping of Haemophilus parasuis.
in Journal of clinical microbiology
Passmore IJ
(2019)
Cytoplasmic glycoengineering of Apx toxin fragments in the development of Actinobacillus pleuropneumoniae glycoconjugate vaccines.
in BMC veterinary research
Bossé JT
(2016)
Complete Genome Sequence of MIDG2331, a Genetically Tractable Serovar 8 Clinical Isolate of Actinobacillus pleuropneumoniae.
in Genome announcements
Donkor ES
(2012)
Comparative phylogenomics of Streptococcus pneumoniae isolated from invasive disease and nasopharyngeal carriage from West Africans.
in BMC genomics
Bossé JT
(2015)
Characterisation of a mobilisable plasmid conferring florfenicol and chloramphenicol resistance in Actinobacillus pleuropneumoniae.
in Veterinary microbiology
Li Y
(2016)
Actinobacillus pleuropneumoniae serovar 8 predominates in England and Wales
in Veterinary Record
Howell KJ
(2017)
"Pathotyping" Multiplex PCR Assay for Haemophilus parasuis: a Tool for Prediction of Virulence.
in Journal of clinical microbiology
| Description | Through this research program we were able to 1) improve the diagnosis, 2) understand the epidemiology and 3) produce improved vaccine candidates against three major pig pathognes Actinobacillus pleuropneumoniae, Streptpcoccos suis and Haemophilus parasuis |
| Exploitation Route | Improved diagositcs, antimicrobials and vaccines |
| Sectors | Agriculture Food and Drink Pharmaceuticals and Medical Biotechnology |
| Description | Bovine Tuberculosis |
| Amount | £11,051,222 (GBP) |
| Funding ID | BB/N004590/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2015 |
| End | 09/2019 |
| Description | DSTL Glycoconjugate vaccine design |
| Amount | £450,000 (GBP) |
| Organisation | Defence Science & Technology Laboratory (DSTL) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2011 |
| End | 09/2014 |
| Description | DSTL Glycoconjugate vaccine design for Coxiella |
| Amount | £600,000 (GBP) |
| Organisation | Defence Science & Technology Laboratory (DSTL) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2012 |
| End | 08/2015 |
| Description | Developing and expanding the bacterial glycotoolbox for animal pathogens |
| Amount | £200,000 (GBP) |
| Funding ID | BB/M01925X/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2015 |
| End | 09/2017 |
| Description | Development and application of an Advanced Glycan Production Platform |
| Amount | £447,107 (GBP) |
| Funding ID | BB/W006146/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 01/2025 |
| Description | Development and testing of a Streptococcus suis glycoconjugate vaccine |
| Amount | £550,000 (GBP) |
| Organisation | Research Councils UK (RCUK) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 03/2021 |
| Description | Development, production and testing of novel glycoconjugate pig vaccines |
| Amount | £600,000 (GBP) |
| Funding ID | BB/S004963/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 02/2021 |
| Description | GlycoCell |
| Amount | £12,300,000 (GBP) |
| Funding ID | BB/Y008472/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2024 |
| End | 02/2029 |
| Description | Glycoengineering of Veterinary Vaccines |
| Amount | £5,300,000 (GBP) |
| Funding ID | BB/N001591/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 04/2021 |
| Title | Provision of bank of E coli glycoengineering strains |
| Description | Provision of bank of E coli glycoengineering strains that are available free from the Belgium Co-ordinated Collection of Microorganisms |
| Type Of Material | Biological samples |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | The bank of E coli glycoengineering strains that are available free from the Belgium Co-ordinated Collection of Microorganisms were the most requested strains from this major collection in 2023, and we were given an award. |
| URL | https://www.biodiversity.be/5177/#:~:text=BCCM%2FLMG%20is%20a%20bacterial,Contact%3A%20lmg%40UGent.b... |
| Description | Hilleman Labs |
| Organisation | MSD Wellcome Trust Hilleman Laboratories |
| Country | India |
| Sector | Charity/Non Profit |
| PI Contribution | Intellectual contribution and vaccine development and production. |
| Collaborator Contribution | Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture |
| Impact | Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture |
| Start Year | 2020 |
| Description | Merck MSD |
| Organisation | Merck |
| Country | Germany |
| Sector | Private |
| PI Contribution | Collaboration on vaccine development |
| Collaborator Contribution | Intellectual contribution and vaccine development and production |
| Impact | Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture |
| Start Year | 2020 |
| Description | Vabiotech vaccine production |
| Organisation | VabioTech |
| Country | Viet Nam |
| Sector | Public |
| PI Contribution | Intellectual contribution and vaccine development and production. |
| Collaborator Contribution | Intellectual contribution and vaccine development and production. |
| Impact | Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture |
| Start Year | 2020 |
| Description | Vaccine development for defence purposes |
| Organisation | Defence Science & Technology Laboratory (DSTL) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | New vaccine technology platform for making glycoconjugate vaccines against Burkholderia pseudomallei and Francisella tulerensis |
| Collaborator Contribution | Technology know how, specific animal testing facilities |
| Impact | Several vaccine candidates tested and some may go forward to vaccine trials |
| Title | Attenuated Streptococcus suis bacterial cells |
| Description | Novel low cost Streptococcal suis vaccine |
| IP Reference | GB1704101.2 |
| Protection | Patent granted |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | Improved pig vaccine |
| Company Name | Arcvax Limited |
| Description | |
| Year Established | 2016 |
| Impact | To rapidly develop low cost candidate glycoconjugate vaccines, eg multiprotective vaccines for poultry. |
| Description | Co-Director of Vaccine Centre |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | As Co-Director of LSHTM vaccines Centre have contributed to several vaccines related event for The General Public, Schools and Industry |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.lshtm.ac.uk/research/centres/vaccine-centre |
| Description | TV Broadcasts |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | BBC Breakfast TV interview on vaccine design and antimicrobial resistance BBC one interview on Campylobacter in Food chain One Show BBC on antimicrobial resistance |
| Year(s) Of Engagement Activity | 2015 |